Pfizer
Pfizer Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Pfizer Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Pfizer Ltd trades at a P/E of 28.58× and P/B of 5.36×.
Valuation
Profitability
Growth
Financial Health
Pfizer Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Pfizer Ltd, switchable between annual and quarterly views, consolidated or standalone.
Pfizer Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹20,641.38 Cr and reported EPS of ₹157.77.
Pfizer segment analysis: revenue and profit mix.
Disclosed business segments at Pfizer with their share of revenue and profit, switchable between consolidated and standalone reporting.
Pfizer discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Pfizer Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Pfizer Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Pfizer Ltd's investment case rests on 8 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Pfizer boasts a strong promoter holding of 63.92% as of September 2025, indicating significant confidence in the company's future prospects and stability. This high ownership stake minimizes potential risks associated with external pressures and ensures long-term strategic alignment.
The company exhibits a healthy Return on Equity (ROE) of 19.80% and Return on Capital Employed (ROCE) of 27.20%, suggesting efficient utilization of shareholder investments and strong operational profitability. These metrics underscore the company's ability to generate returns effectively.
Pfizer maintains a debt-to-equity ratio of 0.00, indicating a virtually debt-free balance sheet. This strong financial position provides significant stability and flexibility, reducing financial risk and enhancing its capacity for future investments or growth initiatives.
Pfizer demonstrated strong profitability in the March 2025 quarter, with net profit significantly increasing to 331.00. This resilience in earnings, despite market challenges, highlights the company's robust business model and ability to generate substantial profits.
The pharmaceutical industry, where Pfizer operates, is poised for growth driven by increasing global healthcare expenditure, an aging population, and rising demand for innovative treatments. This provides a favorable external environment for sustained revenue expansion.
What can break it.
Pfizer's high Price-to-Earnings (P/E) ratio of 157.00 is significantly above the sector P/E of 38.70, suggesting the stock might be overvalued relative to its earnings. This elevated valuation could pose a potential risk for investors if growth expectations are not met.
The company's Operating Profit Margin (OPM) stands at a negative -12.10%, indicating operational inefficiencies that need to be addressed. This negative OPM raises concerns about the company's ability to control costs and generate profit from its core operations.
Recent stock performance shows a declining trend, with the stock closing lower on multiple days in late October 2025, including a -1.01% drop on Oct 23rd. This volatility highlights inherent risk and potential investor apprehension regarding short-term price movements.
Pfizer's Price-to-Book Value (P/B) ratio of 17.40 is quite high, suggesting that the market values the company significantly above its net asset value. This high valuation could limit upside potential and increase downside risk in a market correction.
The pharmaceutical sector faces intense competition from both established players and generic drug manufacturers, potentially leading to pricing pressures and reduced market share for Pfizer. This competitive landscape demands continuous innovation and strategic differentiation.
What would change my mind.
Trim if P/E re-rates above 37. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 2.17. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Pfizer Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Pfizer Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Pfizer Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Pfizer Ltd — derived from the live tape, not yesterday's close.
Pfizer Ltd last traded at ₹4,509.2 with an intraday range of ₹4,501–₹4,578.1 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹4509.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 4712.07 | +202.87 | +4.50% |
| R3 | 4634.97 | +125.77 | +2.79% |
| R2 | 4606.53 | +97.33 | +2.16% |
| R1 | 4557.87 | +48.67 | +1.08% |
| PIVOT | 4529.43 | 20.23 | 0.45% |
| CURRENT | 4509.20 | — | — |
| S1 | 4326.57 | -182.63 | -4.05% |
| S2 | 4403.67 | -105.53 | -2.34% |
| S3 | 4452.33 | -56.87 | -1.26% |
| S4 | 4480.77 | -28.43 | -0.63% |
PFIZER is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 4538.5 ~ 4578.1
Trading Inside opening range
Pfizer Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Pfizer Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Pfizer Ltd stood at 54.4% of traded volume, against a 20-day average of 52.0%.
Pfizer announcements: results, concalls, ratings, M&A.
Filings Pfizer sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Pfizer files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 52 documents below.
Disclosure under SEBI Takeover Regulations
Pfizer Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Copy of Newspaper Publication
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Delay/default in the payment of fines/penalties/dues etc. to authority
Pfizer Limited has informed the Exchange about Delay/default in the payment of fines/penalties/dues etc. to authority
Reply to Clarification- Financial results
The Exchange had sought clarification from Pfizer Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Pfizer dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Pfizer has declared, sequenced by announce and record date.
Pfizer corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Pfizer Ltd: business, sector, key facts.
What Pfizer Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Pfizer Ltd operates in the Healthcare, listed as NSE: PFIZER, BSE: 500680.
Pfizer Limited is a multinational pharmaceutical company with a significant presence in India and international markets. Its core business revolves around the manufacturing, marketing, trading, and export of a wide range of pharmaceutical products. This encompasses a diverse portfolio catering to numerous therapeutic areas, reflecting a broad reach across various health conditions and patient needs.
The company's product portfolio spans a considerable number of therapeutic categories. These include treatments for neurological and central nervous system disorders (neuro/CNS), hormonal imbalances, cardiovascular diseases, haemophilia, infectious diseases (anti-infectives), gynecological conditions, pain management (analgesics), orthopedic issues, cancer (oncology), urological problems, parasitic infections, gastrointestinal disorders, respiratory illnesses, and vaccinations. Furthermore, Pfizer also offers vitamins, minerals, and nutritional supplements.
Pfizer's customer base is extensive and multifaceted. It directly serves healthcare providers, both government and private hospitals, and retail pharmacies. The company's distribution network relies on a system of independent distributors to ensure wide market reach and accessibility of its products. This distribution model allows Pfizer to effectively serve its diverse customer base across various geographical locations and healthcare settings.
In addition to its extensive product offerings, Pfizer Limited also provides internal medicine and anti-infective services directly to hospitals and nursing homes. This reflects a commitment to providing comprehensive healthcare solutions beyond just the supply of pharmaceutical products. This integrated approach strengthens its relationships with healthcare institutions and allows for more holistic patient care.
Established in 1950 and headquartered in Mumbai, India, Pfizer Limited has a long history of operation in the pharmaceutical industry. Its continued success is rooted in its diverse product portfolio, wide-ranging customer base, and established distribution network. The company's commitment to various therapeutic areas underscores its dedication to addressing a broad spectrum of healthcare needs globally.
Questions investors ask about Pfizer Ltd (PFIZER).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Pfizer Ltd (PFIZER)?
The current share price of Pfizer Ltd (PFIZER) is ₹4,509.2. Today, the stock has declined by ₹63.70 (1.39%), trading in a range of ₹4,501 to ₹4,578.1. The stock opened at ₹4,555 with a trading volume of 16,661 shares.
02Is Pfizer Ltd stock a good investment for long-term?
Pfizer Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹20,641.38 crores, P/E ratio of 28.58, ROE of 17.16%, and ROCE of 27.20%. The dividend yield stands at 1.64%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Pfizer Ltd stock?
The 52-week high price of Pfizer Ltd (PFIZER) is ₹0, while the 52-week low is ₹0. Currently trading at ₹4,509.2, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Pfizer Ltd stock at the current price?
Whether to buy Pfizer Ltd stock at ₹4,509.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 28.58 and P/B ratio of 5.36. Today's performance shows a loss of 1.39%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Pfizer Ltd and when is the next dividend?
Pfizer Ltd offers a dividend yield of 1.64%, which means for every ₹100 invested at the current price of ₹4,509.2, you can expect to receive approximately ₹1.64 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Pfizer Ltd?
Pfizer Ltd's key financial metrics include: P/E Ratio: 28.58, P/B Ratio: 5.36, ROE: 17.16%, ROCE: 27.20%, Dividend Yield: 1.64%, EPS: ₹157.77, Book Value: ₹841.24, and Debt-to-Equity: 1.67. The company's market cap stands at ₹20,641.38 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Pfizer Ltd stock performing today in the market?
Pfizer Ltd stock opened at ₹4,555 and is currently trading at ₹4,509.2, showing a decline of ₹63.70 (1.39%). The intraday high is ₹4,578.1 and low is ₹4,501. The trading volume stands at 16,661 shares, indicating moderate market participation today.
08What is the P/E ratio of Pfizer Ltd and what does it indicate?
Pfizer Ltd has a Price-to-Earnings (P/E) ratio of 28.58, which means investors are willing to pay ₹28.58 for every ₹1 of earnings. With an EPS of ₹157.77, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Pfizer Ltd (PFIZER) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy